For non-small-cell lung cancer, the population approved for gefitinib is defined by the presence of specific EGFR mutations [29], whereas for colorectal cancer, patients with KRAS mutations are excluded from treatment by cetuximab [30]. This evidence concerns the gene EGFR and colorectal cancer.